

Processing your request...
Dialog Index Results

Your select statement is 'S TRANSGENIC(6N)POULTRY(6N)VACCIN?' in databases
ALLMEDPH.

☒ **Select All**
☒ **Clear Selections**

<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 5:	<u>BIOSIS Previews® (1969-present)</u>	3
<input type="checkbox"/> 24:	<u>CSA Life Sciences Abstracts</u>	2
<input type="checkbox"/> 34:	<u>SciSearch® - a Cited Reference Science Database - 1990-</u>	1
<input type="checkbox"/> 42:	<u>Pharmaceutical News Index (PNI®)</u>	1
<input type="checkbox"/> 53:	<u>Foodline®: SCIENCE</u>	2
<input type="checkbox"/> 76:	<u>Environmental Sciences</u>	2
<input type="checkbox"/> 88:	<u>Gale Group Business A.R.T.S. (SM)</u>	1
<input type="checkbox"/> 192:	<u>Industry Trends and Analysis</u>	1
<input type="checkbox"/> 266:	<u>Federal Research in Progress (FEDRIP)</u>	1
<input type="checkbox"/> 286:	<u>BioCommerce Data's Biotechnology Directory</u>	2
<input type="checkbox"/> 340:	<u>CLAIMS®/U.S. Patents</u>	1
<input type="checkbox"/> 357:	<u>Derwent Biotechnology Resource</u>	1
<input type="checkbox"/> 399:	<u>CA SEARCH® - Chemical Abstracts® (1967-present)</u>	5
<input type="checkbox"/> 484:	<u>Periodical Abstracts PlusText(TM)</u>	1
<input type="checkbox"/> 636:	<u>Gale Group Newsletter Database(TM)</u>	1
<input type="checkbox"/> 654:	<u>U.S. Patents Fulltext (1976-present)</u>	1
<input type="checkbox"/> 764:	<u>BCC Market Research</u>	1

There are 17 databases matching your statement 'S TRANSGENIC (6N)POULTRY(6N)VACCIN?'.

☒ **Select All**
☒ **Clear Selections**

© 2006 Dialog, a Thomson business

Processing your request...
Dialog Index Results

Your select statement is 'S (HYBRID OR CHIMER?)(5N)(LT OR HLT)(6N)(PLANT? OR TRANSGENIC)' in databases ALLMEDPH.

☒ **Select All** ☒ **Clear Selections** **Begin Databases** **New Search**
Sort Results

<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 5:	<u>BIOSIS Previews® (1969-present)</u>	5
<input type="checkbox"/> 16:	<u>Gale Group PROMT® (1990 - present)</u>	1
<input type="checkbox"/> 285:	<u>BioBusiness®</u>	3
<input type="checkbox"/> 348:	<u>European Patents Fulltext</u>	1
<input type="checkbox"/> 349:	<u>WIPO/PCT Patents Fulltext</u>	6
<input type="checkbox"/> 399:	<u>CA SEARCH® - Chemical Abstracts® (1967-present)</u>	1
<input type="checkbox"/> 654:	<u>U.S. Patents Fulltext (1976-present)</u>	3

There are 7 databases matching your statement 'S (HYBRID OR CHIMER?)(5N)(LT OR HLT)(6N) (PLANT? OR TRANSGENIC)'.

© 2006 Dialog, a Thomson business

Processing your request...
Dialog Index Results

Your select statement is 'S FUSION(5N)(LT OR HLT)(6N)(PLANT? OR TRANSGENIC)' in
databases ALLMEDPH.

☒ Select All
☒ Clear Selections

<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 5:	<u>BIOSIS Previews® (1969-present)</u>	1
<input type="checkbox"/> 10:	<u>AGRICOLA</u>	1
<input type="checkbox"/> 24:	<u>CSA Life Sciences Abstracts</u>	2
<input type="checkbox"/> 34:	<u>SciSearch® - a Cited Reference Science Database - 1990-</u>	2
<input type="checkbox"/> 35:	<u>Dissertation Abstracts Online</u>	1
<input type="checkbox"/> 45:	<u>EMCare®</u>	1
<input type="checkbox"/> 50:	<u>CAB ABSTRACTS</u>	2
<input type="checkbox"/> 71:	<u>Elsevier Biobase</u>	1
<input type="checkbox"/> 73:	<u>EMBASE® (1974-present)</u>	1
<input type="checkbox"/> 88:	<u>Gale Group Business A.R.T.S. (SM)</u>	1
<input type="checkbox"/> 98:	<u>Wilson General Science Abstracts</u>	1
<input type="checkbox"/> 99:	<u>Wilson Applied Science & Technology Abstracts</u>	1
<input type="checkbox"/> 135:	<u>NewsRX Weekly Reports</u>	1
<input type="checkbox"/> 144:	<u>PASCAL</u>	1
<input type="checkbox"/> 149:	<u>Gale Group Health & Wellness Database(SM)</u>	1
<input type="checkbox"/> 155:	<u>MEDLINE® (1950-present)</u>	1
<input type="checkbox"/> 156:	<u>TOXFILE</u>	1
<input type="checkbox"/> 324:	<u>German Patents Fulltext</u>	1
<input type="checkbox"/> 348:	<u>European Patents Fulltext</u>	3
<input type="checkbox"/> 349:	<u>WIPO/PCT Patents Fulltext</u>	6
<input type="checkbox"/> 440:	<u>Current Contents Search®</u>	2
<input type="checkbox"/> 484:	<u>Periodical Abstracts PlusText(TM)</u>	1
<input type="checkbox"/> 636:	<u>Gale Group Newsletter Database(TM)</u>	1
<input type="checkbox"/> 654:	<u>U.S. Patents Fulltext (1976-present)</u>	12

There are 24 databases matching your statement 'S FUSION(5N)(LT OR HLT)(6N)(PLANT? OR TRANSGENIC)'.

☒ Select All
☒ Clear Selections

© 2006 Dialog, a Thomson business

Refine Search

Search Results -

Terms	Documents
transgenic same (avian or poultry or bird or chicken) adj influenza	11

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L4

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, August 30, 2006 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>		
<u>L4</u>	transgenic same (avian or poultry or bird or chicken) adj influenza	11	<u>L4</u>
<u>L3</u>	transgenic same Newcastle	15	<u>L3</u>
<u>L2</u>	transgenic same (fused or fusion or hybrid or chimer\$ or genet\$) same (LT or HLT or heat adj labile adj toxin\$)	33	<u>L2</u>
<u>L1</u>	transgenic same (fused or fusion or hybrid or chimer\$ or genet\$) same (LT or HLT or heat adh labile adj toxin\$)	515	<u>L1</u>

END OF SEARCH HISTORY

TYPED

Document Type: Journal Article
Record Type: Abstract
Language: English
Summary Language: English
ISSN: 0014-2980
File Segment: Immunology Abstracts

Abstract:

NK cells lyse tumor, virus-infected and allogeneic cells through a recognition system involving inhibitory and activating receptors, among which are the Ly49 molecules that recognize MHC class I proteins. To date, little is known about the regulation of Ly49 expression during NK cell development. In this study we report that the acquisition of Ly49 receptors by NK cells is significantly reduced in lymphotoxin (LT) alpha -deficient mice, whereas it is increased in LT alpha transgenic mice. Treating normal mice with LT beta R-Ig fusion protein reduced Ly49 expression, indicating that regulation of Ly49 receptor expression occurs through the engagement of membrane LT to LT beta R, and not soluble LT to TNFR. In addition, when LT alpha super(-/-) mice were treated exogenously with recombinant IL-15, NK cell numbers as well as Ly49 acquisition were restored to wild-type levels. Finally, using real-time PCR analyses of bone marrow cells obtained from LT-deficient or transgenic mice, we show a direct correlation between LT beta R activation and increased IL-15 transcription. These data suggest that LT beta R-mediated signals regulate Ly49 expression at least in part through the activation of IL-15.

Abstract

CSA Life Sciences Abstracts (Dialog® File 24): (c) 2006 CSA. All rights reserved.

Dialog eLink:

USPTO Full Text Retrieval Options

[open url](#)

[open url](#)

3. ☒ 2/3,AB/3 (Item 1 from file: 34)
15212738 **Genuine Article#:** 047GX **Number of References:** 22
Expression of tuberculosis antigen ESAT-6 in Nicotiana tabacum using a potato virus X-based vector
(ABSTRACT AVAILABLE)
Author: Zelada AM (REPRINT) ; Calarnante G; Santangelo MD; Bigi F; Verna F; Mentaberry A; Cataldi A
Corporate Source: Consejo Nacl Invest Cient & Tecn,Inst Invest Ingn Genet & Biol Mol,Vuelta Obligado 2490/RA-1428 Buenos Aires/DF/Argentina/ (REPRINT); Consejo Nacl Invest Cient & Tecn,Inst Invest Ingn Genet & Biol Mol,RA-1428 Buenos Aires/DF/Argentina/; Univ Buenos Aires,FCEN,RA-1428 Buenos Aires/DF/Argentina/; INTA,Inst Biotecnol,Castelar//Argentina/ (azelada@dna.uba.ar)
Journal: TUBERCULOSIS , 2006 , V 86 , N3-4 (MAY-JUL) , P 263-267
ISSN: 1472-9792 **Publication date:** 20060500
Publisher: CHURCHILL LIVINGSTONE , JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
Language: English **Document Type:** ARTICLE
Abstract: A good candidate antigen to create a therapeutic vaccine against TB is the ESAT-6 protein. Antigens produced in plants have already been successfully used as experimental vaccines, and small single-stranded RNA plant viruses have emerged as promising tools to rapidly express large amounts of foreign proteins in susceptible host plants. Here, we present the expression of ESAT-6 protein in Nicotiana tabacum using a vector based on potato virus X (PVX). The complete ESAT-6 open reading frame is expressed as a fusion protein with the 2A

peptide of Foot and Mouth Disease Virus and the amino terminal of the PVX coat protein (CP) (PVXESAT-6). This strategy allows the production of free CP and ESAT-6 as well as fused ESAT-2A-CP to obtain recombinant chimaeric virions expressing ESAT-6 at the surface to be used as particulate antigen in vaccination. ESAT-6 expression was tested in agroinfiltrated tobacco leaves and products of the expected molecular masses corresponding to cleaved CP and ESAT-2A-CP fusion protein were observed, with ESAT-6 yields ranging from 0.5% to 1% of total soluble protein. Our study describes for the first time the expression of the ESAT-6 protein in tobacco plants using a PVX-derived vector. This strategy should serve as a convenient, rapid, low-cost expression system and can also be used for the assessment of ESAT-6 production and function prior to stable plant transformation. (c) 2006 Elsevier Ltd. All rights reserved.

SciSearch(R) Cited Ref Sci (Dialog® File 34): (c) 2006 The Thomson Corp. All rights reserved.

-
4. ☒ 2/3,AB/4 (Item 1 from file: 35)
01905232

Maize as production and delivery vehicle of edible vaccines against the enterotoxigenic *Escherichia coli* and the swine transmissible gastroenteritis (TGE)

Author: Chikwamba, Rachel Kerina

Degree: Ph.D.

Year: 2002

Corporate Source/Institution: Iowa State University (0097)

Source: Volume 6308B of Dissertations Abstracts International.

PAGE 3532 . 209 PAGES

ISBN: 0-493-77797-0

Plants are becoming increasingly important as a production system for biopharmaceuticals and industrially important proteins. The work presented in this dissertation showed that maize can be used as a source and delivery vehicle for oral vaccines. Antigenic proteins from two economically important pathogens, enterotoxigenic *Escherichia coli* (*E. coli*) and the swine transmissible gastroenteritis virus (TGEV) were expressed in transgenic maize.

This study showed that subunits of the *E. coli* heat labile enterotoxin (LT) can be synthesized in transgenic maize tissues, correctly processed and assembled in maize tissue. The role of regulatory sequences such as promoters, targeting and retention signals in accumulation of LT-B in transgenic maize kernels was studied. The seed specific 27 kDa gamma zein promoter achieved a significantly higher level of LT-B expression in kernels compared to the constitutive CaMV 35S promoter. The use of the endoplasmic reticulum retention motif SEKDEL significantly enhanced kernel accumulation of LT-B. The LT-13 gene was normally transmitted over three generations.

Maize generated LT-B had biochemical, biophysical, and immunogenic properties of the bacterial protein. Oral administration of transgenic maize expressing LT-B in BALB/c mice induced elevated titers of serum and mucosal antibodies, which protected the immunized animals from subsequent challenge with LT and Cholera toxin (CT).

Using two synthetic genes for the LT toxin subunits, LT-A and LT-B, a non-toxic derivative of the heat labile toxin, LTK63, was expressed in transgenic maize callus. This mutant toxin assembled in maize callus tissue, showing that complex folding of foreign antigens could be achieved in transgenic maize tissues. This mutant derivative was shown to be more immunogenic than the bacteria derived LT-B.

We fused an N-terminal domain of the spike (S) protein of the swine transmissible gastroenteritis virus to the A subunit of LT, and coexpressed this fusion with LT-B in transgenic

maize callus. Expression of the fusion proteins and LT-B was observed in callus.

This work demonstrates that maize, a key ingredient in food and feed industry, can be used as a source and delivery vehicle of functional antigens for use as oral vaccines. Maize holds great potential for the generation of human and livestock vaccines, and this work lays the foundation for the development of vaccines against other pathogens in transgenic maize.

Dissertation Abs Online (Dialog® File 35): (c) 2006 ProQuest Info&Learning. All rights reserved.

Dialog eLink: **USPTO Full Text Retrieval Options** **PNAS** [open url](#) [open url](#)

5. ☒ 2/3,AB/5 (Item 1 from file: 50)

0006306099 **CAB Accession Number:** 19900181279

Spatial differentiation of the intestinal epithelium: analysis of enteroendocrine cells containing immunoreactive serotonin, secretin, and substance P in normal and transgenic mice.

Roth, K. A.; Gordon, J. I.

Department of Pathology, Washington University School of Medicine, Saint Louis, MO 63110, USA.

Proceedings of the National Academy of Sciences of the United States of America vol. 87 (16): p.6408-6412

Publication Year: 1990

ISSN: 0027-8424

Language: English **Record Type:** Abstract

Document Type: Journal article

Transgenic mice carrying a rat liver fatty-acid binding protein-human growth hormone fusion gene were used in a study of enteroendocrine cell differentiation in the intestine.

Immunocytochemical methods were used to characterise the spatial relationships of the serotonin-, secretin- and substance P-containing enteroendocrine cell subsets in normal adult C57BL/6J X LT/Sv mice as well as transgenic littermates containing the fusion gene. Precise interrelationships between the cell populations were revealed, and a differentiation pathway that may involve the sequential expression of substance P, serotonin and secretin is proposed. 24 ref.

CAB Abstracts (Dialog® File 50): (c) 2006 CAB International. All rights reserved.

6. ☒ 2/3,AB/6 (Item 1 from file: 135)

0000003845 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Transgenic Plants May Advance Subunit Vaccines

Boyles, Salynn

Vaccine Weekly, July 3, 1995, p.14-15

DOCUMENT TYPE: Editor's Choice **LANGUAGE:** English

RECORD TYPE: FULLTEXT

Word Count:

481

7. ☒ 2/3,AB/7 (Item 1 from file: 144)

12097522 PASCAL No.: 95-0326451

Oral immunization with a recombinant bacterial antigen produced in transgenic plants : The emerging world of plant science : frontiers in biotechnology

HAQ T A; MASON H S; CLEMENTS J D; ARNTZEN C J
Texas A&M univ., Abert B. Alkek inst. biosci. technology, plant
biotechnology program, Houston TX 77030, USA
Journal: Science : (Washington, DC),
1995, 268 (5211)
714-716

Language: English

The binding subunit of Escherichia coli heat-labile enterotoxin (LT-B) is a highly active oral immunogen. Transgenic tobacco and potato plants were made with the use of genes encoding LT-B or an LT-B fusion protein with a microsomal retention sequence. The plants expressed the foreign peptides, both of which formed oligomers that bound the natural ligand. Mice immunized by gavage produced serum and gut mucosal anti-LT-B immunoglobulins that neutralized the enterotoxin in cell protection assays. Feeding mice fresh transgenic potato tubers also caused oral immunization

Pascal (Dialog® File 144): (c) 2006 INIST/CNRS. All rights reserved.

8. ☒ 2/3,AB/8 (Item 1 from file: 324)

0003142799

Procedure and device for suspension melts
Verfahren und Vorrichtung zum Suspensionsschmelzen

Patent Applicant/Assignee:

Outokumpu Engineering Contractors OY, Espoo, FI

Inventor(s):

Hanniala Pekka, Espoo, FI

Saarinen Risto, Espoo, FI

Krogerus Erkki, Kirkkonummi, FI

Kojo Ilkka, Masala, FI

Patent and Priority Information (Country, Number, Date):

Patent: DE 19505339 A1 19950824

Application: DE 19505339 19950216

Priority Application: FI 94739 19940217 (FI 940739)

Publication Language: German

Fulltext Word Count (English): 3916

Fulltext Word Count (German) : 3197

Fulltext Word Count (Both) : 7113

Abstract (English machine translation)

The invention concerns a procedure and a device to suspension melts of sulfidischer finely divided raw materials, which metals e.g. copper, nickel and lead contain, using an oxygenisation. With this procedure the

raw materials which can be melted (4, 5) are supplied to the suspension melting furnace (1) together with a fluxing agent (6) and oxidizing gas (7). The walls (18) of the reaction area of the suspension melting furnace are cooled, and at least two melted phases (16, 17) are produced. The degree of the oxygenisation amounts to according to invention at least 40%, in order to raise the temperature of the particles in the suspension over at least 200degreesC over the temperature of the gaseous phase in the suspension, in order to improve thereby the reaction kinetics of the reactions taking place in the reaction area. Further the thickness of the lining of the reaction area according to the throughput by the suspension melting furnace by means of cooling sections (20) adjusted, which are arranged by pulling pouring manufactured and in the wall of the reaction area.

Abstract (German)

Die Erfindung betrifft ein Verfahren und eine Vorrichtung zum Suspensionsschmelzen sulfidischer feinverteilter Rohstoffe, die Metalle wie z. B. Kupfer, Nickel und Blei enthalten, unter Verwendung einer Sauerstoffanreicherung. Bei diesem Verfahren werden dem Suspensionsschmelzofen (1) die zu schmelzenden Rohstoffe (4, 5) zusammen mit einem Flussmittel (6) und oxidierenden Gas (7) zugeführt. Die Wände (18) des Reaktionsraumes des Suspensionsschmelzofens werden gekühlt, und es werden zumindest zwei geschmolzene Phasen (16, 17) erzeugt. Erfindungsgemäss beträgt der Grad der Sauerstoffanreicherung zumindest 40%, um die Temperatur der Partikel in der Suspension um zumindest 200degreesC über die Temperatur der Gasphase in der Suspension anzuheben, um hierdurch die Reaktionskinetik der im Reaktionsraum stattfindenden Reaktionen zu verbessern. Weiterhin wird die Dicke der Auskleidung des Reaktionsraums entsprechend dem Durchsatz durch den Suspensionsschmelzofen mittels Kühlelemente (20) eingestellt, die durch Ziehgiessen hergestellt und in der Wand des Reaktionsraums angeordnet sind.

German Patents Fulltext (Dialog® File 324): (c) 2006 Univentio. All rights reserved.

-
9. ☒ 2/3,AB/9 (Item 1 from file: 348)
02082571

Oral vaccines for fish

Title in German: Orale Impfstoffe für Fische

Title in French: Vaccins oraux pour poissons

Patent Assignee: Plant Research International B.V., (3166440), Droevendaalsesteeg 1, 6708 PB Wageningen, (NL), (Applicant designated States: all)

Inventor: Florack, Dionisius Elisabeth Antonius, van Doesburglaan 160, 6708 MD Wageningen, (NL)
Bosch, Hendrik Jan, Wim Sonneveldstraat 17, 6708 NA Wageningen, (NL)

Legal Representative: Winckels, Johannes Hubertus F. et al (22024), Verenigde, Johan de Wittlaan 7, 2517 JR Den Haag, (NL)

	Patent Number	Kind	Date
Patent	EP 1685848	A1	060802 (Basic)
Application	EP 2005075203		050126

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR

INTERNATIONAL CLASSIFICATION (V8 + ATTRIBUTES) :

IPC + Level Value Position Status Version Action Source Office:

A61K-0039/12 A I F B 20060101 20050830 H EP

A61K-0039/385 A I L B 20060101 20050830 H EP

Language (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200631	404
SPEC A	(English)	200631	8113

Total word count	Document A	8517
Total word count	Document B	0
Total word count	Document A + B	8517

EUROPEAN PATENTS (Dialog® File 348): (c) 2006 European Patent Office. All rights reserved.

10. ☒ 2/3,AB/10 (Item 2 from file: 348)
01945362

Sequence-determined DNA fragments and corresponding polypeptides encoded thereby

Title in German: DNA-Fragmente mit bestimmter Sequenz und die dadurch kodierte Polypeptide

Title in French: Fragments d'ADN avec des sequences determinees et polypeptides encodees par lesdits fragments

Patent Assignee: Ceres Incorporated, (2967260), 3007 Malibu Canyon Road, Malibu, CA 90265, (US), (Applicant designated States: all)

Inventor: Alexandrov, Nickolai, 1404 Oak Trail Street, Thousand Oaks, CA 91320, (US)
Brover, Vyacheslav, 1741 N. Warfield Circle, Simi Valley, CA 93063, (US)
Chen, Xianfeng, 1705 S. Westgate Avenue, no. 2, Los Angeles, CA 90025, (US)

Subramanian, Gopalkrishnan, 4205 Peach Slope Road, Moorpark, CA 93021, (US)
 Troukhan, Maxim E., 29425 Hillrise Drive, Agoura Hills, CA 91301, (US)
 Zheng, Liansheng, 19212 Circle Gate Drive, no. 201, Germantown, MD 20874, (US)
 Dumas, J., 8 rue de Gregoire-de-Tours, Paris, (FR)

Legal Representative: Elsy, David et al (94121), Withers & Rogers LLP Goldings House, 2 Hays Lane, London SE1 2HW, (GB)

	Patent Number	Kind	Date	
Patent	EP 1568773	A2	050831 (Basic)	
	EP 1586645	A2	051019	
	EP 1586645	A3	060222	
Application	EP 2004017692		000225	
Priority	US 121825		P	990225
	US 123180		P	990305
	US 123548		P	990309
	US 125788		P	990323
	US 126264		P	990325
	US 126785		P	990329
	US 127462		P	990401
	US 129845		P	990416
	US 130077		P	990419
	US 130449		P	990421
	US 130891		P	990423
	US 130510		P	990423
	US 132407		P	990430
	US 132484		P	990504
	US 132485		P	990505
	US 132863		P	990507
	US 134256		P	990511
	US 134218		P	990514
	US 134219		P	990514
	US 139452		P	990616
	US 139453		P	990616
	US 139461		P	990618
	US 139463		P	990618
	US 139457		P	990618

	US 139459		P	990618
	US 139462		P	990618
	US 139455		P	990618
	US 139458		P	990618
	US 139454		P	990618
	US 139456		P	990618
	US 139460		P	990618
	US 144085		P	990716
	US 144086		P	990716
	US 144333		P	990719
	US 144335		P	990719
	US 144334		P	990719
	US 144884		P	990720
	US 144352		P	990720
	US 145145		P	990723
	US 145224		P	990723
	US 145919		P	990727
	US 145918		P	990727
	US 146388		P	990802
	US 146389		P	990802
	US 147302		P	990804
	US 147192		P	990805
	US 147303		P	990806
	US 147935		P	990809
	US 148171		P	990810
	US 148684		P	990813
	US 149368		P	990816
	US 149929		P	990820
	US 149930		P	990823
	US 132486		P	990506
	US 144332		P	990719
	US 144331		P	990719
	US 145086		P	990721
	US 145088		P	990721
	US 145085		P	990722
	US 145089		P	990722
	US 145087		P	990722

Designated States: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
International Patent Class: C12N-015/29; C12N-015/82; C07K-014/415; C12Q-001/68; A01H-005/00

INTERNATIONAL PATENT CLASS (V7): C12N-015/29; C12N-015/82; C07K-014/415; C12Q-001/68; A01H-005/00

INTERNATIONAL CLASSIFICATION (V8 + ATTRIBUTES):

IPC + Level Value Position Status Version Action Source Office:

C12N-0015/29	A	I	F	B	20060101	20050616	H	EP
C12N-0015/82	A	I	L	B	20060101	20050616	H	EP
C07K-0014/415	A	I	L	B	20060101	20050616	H	EP
C12Q-0001/68	A	I	L	B	20060101	20050616	H	EP
A01H-0005/00	A	I	L	B	20060101	20050616	H	EP

Abstract EP 1586645 A3

The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3' termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.

Abstract Word Count: 106

Language (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200542	1210
SPEC A	(English)	200542	195251

Total word count	Document A	196496
Total word count	Document B	0
Total word count	Document A + B	196496

EUROPEAN PATENTS (Dialog® File 348): (c) 2006 European Patent Office. All rights reserved.

11. ☒

2/3,AB/11 (Item 3 from file: 348)
00774090

ORAL IMMUNIZATION WITH TRANSGENIC PLANTS

Title in German: ORALE IMMUNISIERUNG DURCH VERWENDUNG VON TRANSGENEN PFLANZEN

**Title in French: IMMUNISATION PAR VOIE ORALE A L'AIDE DE PLANTES
TRANSGENIQUES**

Patent Assignee: The Texas A & M University System, (5007400), 3369 TAMU,
College Station, Texas 77843-3369, (US), (Proprietor designated states:
all)
THE ADMINISTRATORS OF THE TULANE UNIVERSITY
EDUCATIONAL FUND, (762745), 1430 Tulane Avenue, Tulane
University, New Orleans, Louisiana 70112-2699, (US), (Proprietor
designated states: all)

Inventor: ARNTZEN, Charles J., Tower Road, Ithaca, NY 14853-1801, (US)
MASON, Hugh S., Tower Road, Ithaca, NY 14853-1801, (US)
HAQ, Tariq A., 2121 West Holcombe Boulevard, Houston, TX 77030-
3303, (US)
CLEMENTS, John D., 1430 Tulane Avenue, New Orleans, LA 70112,
(US)

Legal Representative: Woods, Geoffrey Corlett et al (48721), J.A. KEMP & CO. Gray's Inn
14 South Square, London WC1R 5JJ, (GB)

	Patent Number	Kind	Date
Patent	EP 793717	A1	970910 (Basic)
	EP 793717	A1	981125
	EP 793717	B1	050126
	WO 1996012801		960502
Application	EP 95940519		951024
	WO 95US13376		951024
Priority	US 328716		941024

Designated States: AT; BE; DE; ES; FR; GB; IT; NL

International Patent Class: C12N-015/00; C12N-015/05; C12N-015/09; C12N-015/63; C12N-
015/70; C12N-015/74; C12N-015/82; C12P-021/04; C12P-021/06;
A01H-005/00; C07K-014/245; C07K-014/08

INTERNATIONAL PATENT CLASS (V7): C12N-015/00; C12N-015/05; C12N-015/09;
C12N-015/63; C12N-015/70; C12N-015/74; C12N-015/82; C12P-021/04; C12P-021/06;
A01H-005/00; C07K-014/245; C07K-014/08

Language (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200504	471
CLAIMS B	(German)	200504	448
CLAIMS B	(French)	200504	489
SPEC B	(English)	200504	24104

Total word count	Document A	0
Total word count	Document B	25512
Total word count	Document A + B	25512

EUROPEAN PATENTS (Dialog® File 348): (c) 2006 European Patent Office. All rights reserved.

12. ☒ 2/3,AB/12 (Item 1 from file: 349)
01399574

ORAL VACCINES FOR FISH
VACCINS ORAUX POUR POISSONS

Patent Applicant/Assignee:

Plant Research International BV, Droevendaalsesteeg 1, NL-6708 PB Wageningen, NL, NL
(Residence), NL (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

FLORACK Dionisius Elisabeth Antonius, Van Doesburglaan 160, NL-6708 MD Wageningen,
NL, NL (Residence), NL (Nationality), (Designated only for: US)

BOSCH Hendrik Jan, Wim Sonneveldstraat 17, NL-6708 NA Wageningen, NL, NL
(Residence), NL (Nationality), (Designated only for: US)

Legal Representative:

WINCKELS Jhf (agent), C/o Vereenigde, Johan De Wittlaan 7, NL-2517 JR The Hague, NL

Patent and Priority Information (Country, Number, Date):

Patent: WO 20060842 A2 20060803 (WO 0680842)

Application: WO 2006NL44 20060126 (PCT/WO NL2006000044)

Priority Application: EP 2005752039 20050126

Designated States:

(All protection types applied unless otherwise stated - for applications 2004+)

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR
KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM
PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC
VN YU ZA ZM ZW

(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL
PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 9930

English Abstract

The invention relates to the development, composition and production of mucosal (oral) vaccines for fish. More specifically, the invention relates to protein complexes for the delivery of antigens to and across mucosal surfaces of fish for the induction of an immune response, and to the production of said complexes in a host cell, preferably plants. Provided is the use of a protein complex comprising an antigen of interest fused to the B-subunit of *Vibrio cholerae* cholera toxin (CT-B), or *Escherichia coli* heat-labile enterotoxin (LT-B) for the manufacture of an oral fish vaccine. Also provided is fish feed comprising a protein complex of the invention

French Abstract

L'invention concerne l'elaboration, la composition et la production de vaccins mucosiques (oraux) pour poissons. Plus specifiquement, l'invention concerne des complexes proteiques servant a liberer des antigenes sur les surfaces des muqueuses et dans les muqueuses des poissons pour provoquer une reponse immunitaire; l'invention concernant egalement la production desdits complexes dans une cellule hote, de preference des plantes. Par ailleurs, l'invention concerne l'utilisation d'un complexe proteique contenant un antigene recherche fusionne sur la sous-unite B de la toxine du cholera (CT-B) de *Vibrio cholerae*, ou l'enterotoxine thermolabile (LT-B) d'*Escherichia coli*, dans la mise au point d'un vaccin oral pour poissons. L'invention concerne en outre un aliment pour poisson qui contient un complexe proteique de l'invention.

PCT FULLTEXT (Dialog® File 349): (c) . All rights reserved.

13. ☒ 2/3,AB/13 (Item 2 from file: 349)
00950932

**METHODS AND COMPOSITIONS FOR STABLE TRANSGENIC PLANT
PHARMACEUTICALS AND THEIR USE AS CONTRACEPTIVES
METHODES ET COMPOSITIONS POUR MEDICAMENTS STABLES A BASE DE
PLANTES TRANSGENIQUES ET LEUR UTILISATION COMME CONTRACEPTIFS**

Patent Applicant/Assignee:

BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, Tower Road, Ithaca, NY 14853-1801, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

KIRK Dwayne, 3427 N. Sericin Street, Mesa, AZ 85215, US, US (Residence), AU (Nationality), (Designated only for: US)

MASON Hugh, 1311 Hanshaw Road, Ithaca, NY 14850, US, US (Residence), US (Nationality), (Designated only for: US)

WALMSLEY Amanda, 3427 N. Sericin Street, Mesa, AZ 85215, US, US (Residence), AU (Nationality), (Designated only for: US)

ARNTZEN Charles, 7686 E. Wilderness Trail, Superstition Mountain, AZ 85216-1806, US, US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WILLIAMS Kathleen M (agent), Palmer & Dodge LLP, 111 Huntington Avenue, Boston, MA 02199-7613, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200283072 A2-A3 20021024 (WO 0283072)

Application: WO 2002US11693 20020412 (PCT/WO US0211693)

Priority Application: US 2001283884 20010413

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM
DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG
SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English
Filing Language: English
Fulltext Word Count: 29200

English Abstract

The present invention provides for processing methods that preserve pharmaceutical proteins expressed in plants. Herein raw plant tissue is reduced to a stable homogenate without significant loss of protein or pharmaceutical potency. The homogenate can be used directly for pharmaceutical purposes without the need to further extract, purify, or precipitate the pharmaceutical protein. The present invention further provides a method of effective immunocontraception for animal and human application. Methods are disclosed for producing transgenic plant or plant cells which express contraceptive proteins, and which can be delivered whole, in part, or after processing, to an animal to cause a contraceptive effect in the target species.

French Abstract

L'invention concerne des methodes de traitement preservant des proteines pharmaceutiques exprimees dans des plantes. On reduit un tissu vegetal brut en un homogenat stable sans perte significative de proteine ou d'activite pharmaceutique. On peut utiliser ledit homogenat directement a des fins pharmaceutiques sans avoir recours a une extraction, une purification, ou une precipitation ulterieure de la proteine pharmaceutique. L'invention concerne egalement un procede d'immunocontraception efficace pour une application animale et humaine. L'invention concerne enfin des procedes permettant de produire des plantes transgeniques ou des cellules vegetales exprimant des proteines contraceptives, et pouvant etre distribuees en totalite, partiellement ou apres traitement a un animal afin d'obtenir un effet contraceptif chez des especes cibles.

PCT FULLTEXT (Dialog® File 349): (c) . All rights reserved.

-
14. ☒ 2/3,AB/14 (Item 3 from file: 349)
00864262

WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
INGENIERIE CELLULAIRE COMPLETE PAR MUTAGENESE D'UNE PARTIE SUBSTANTIELLE D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT REPETITION

Patent Applicant/Assignee:

DIVERSA CORPORATION, 4955 Directors Place, San Diego, CA 92121, US, US
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

SHORT Jay M, 6801 Paseo Delicias, P.O. Box 7214, Rancho Santa Fe, CA 92067-7214, US,
US (Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HAILE Lisa A (agent), Gray Cary Ware & Freidenrich LLP, Suite 1100, 4365 Executive Drive,
San Diego, CA 92121-2133, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200196551 A2-A3 20011220 (WO 0196551)

Application: WO 2001US19367 20010614 (PCT/WO US0119367)

Priority Application: US 2000594459 20000614; US 2000677584 20000930

Parent Application/Grant:

Related by Continuation to: US 2000594459 20000614 (CIP); US 2000677584 20000930 (CIP)

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM
DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK
SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 336587

English Abstract

An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products.

French Abstract

L'invention porte sur des procedes de transformation cellulaire, d'evolution dirigee et de criblage en vue de creer de nouveaux organismes transgeniques aux proprietes souhaitees. En variante, cette invention porte sur un procede de generation d'un organisme transgenique tel qu'un microbe ou une plante presentant une pluralite de caracteristiques pouvant etre activees de maniere differentielle. L'invention porte aussi sur un procede permettant de restructurer des genes et des mecanismes d'action genetiques par l'introduction de sequences regulatrices telles que des promoteurs pouvant agir dans un hote determine, ce qui confere une operabilite a un nouveau mecanisme d'action genetique lorsqu'il est introduit dans un hote determine. Par exemple, un nouveau mecanisme d'action genetique artificiel, genere a partir de gabarits de progeniteurs derives de microbes, peut etre utilise dans une cellule vegetale. L'invention porte en outre sur de nouveaux organismes hotes dont les caracteristiques souhaitees, les genes de recombinaison et les produits geniques ont une expression accrue.

PCT FULLTEXT (Dialog® File 349): (c) . All rights reserved.

-
15. ☒ 2/3,AB/15 (Item 4 from file: 349)
00518527

**SEQUENCE AND METHOD FOR GENETIC ENGINEERING OF PROTEINS WITH
CELL MEMBRANE TRANSLOCATING ACTIVITY**

**SEQUENCE ET METHODE DESTINEES A LA PRODUCTION PAR GENIE
GENETIQUE DE PROTEINES PRESENTANT UNE ACTIVITE DE**

TRANSLOCATION DE LA MEMBRANE CELLULAIRE

Patent Applicant/Assignee:

VANDERBILT UNIVERSITY,

Inventor(s):

LIN Yao-Zhong,

DONAHUE John P,

ROJAS Mauricio,

TAN Zhong Jia,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9949879 A1 19991007

Application: WO 99US7189 19990331 (PCT/WO US9907189)

Priority Application: US 9880083 19980331; US 98186170 19981104

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 16645

English Abstract

The invention describes a membrane-translocating peptide sequence (MTS) which facilitates entry of polypeptides and proteins into cells. Also described is an isolated nucleotide sequence encoding the membrane-translocating peptide and a method of using this sequence to genetically engineer proteins with cell membrane permeability. The MTS, and the method of genetically engineering proteins with cell membrane permeability, are useful for polypeptide and protein delivery for human and veterinary applications such as vaccine delivery and cancer therapy.

French Abstract

L'invention concerne une sequence peptidique de translocation membranaire facilitant la penetration des polypeptides et de proteines dans les cellules. L'invention concerne egalement une sequence nucleotidique isolee codant le peptide de translocation membranaire, et une methode d'utilisation de cette sequence pour produire, par genie genetique, des proteines presentant une permeabilite de la membrane cellulaire. La sequence peptidique de translocation membranaire, et la methode de production, par genie genetique, de proteines presentant une permeabilite de la membrane cellulaire, sont utiles pour l'apport de polypeptides et de proteines en vue d'applications humaines et veterinaires telles que l'administration de vaccins et le traitement du cancer.

PCT FULLTEXT (Dialog® File 349): (c) . All rights reserved.

-
16. ☒ 2/3,AB/16 (Item 5 from file: 349)

00330290

ORAL IMMUNIZATION WITH TRANSGENIC PLANTS

IMMUNISATION PAR VOIE ORALE A L'AIDE DE PLANTES TRANSGENIQUES

Patent Applicant/Assignee:

THE TEXAS A & M UNIVERSITY SYSTEM,

THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND,

ARNTZEN Charles J,

MASON Hugh S,

HAQ Tariq A,
CLEMENTS John D,

Inventor(s):

ARNTZEN Charles J,
MASON Hugh S,
HAQ Tariq A,
CLEMENTS John D,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9612801 A1 19960502

Application: WO 95US13376 19951024 (PCT/WO US9513376)

Priority Application: US 94328716 19941024

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP
KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ
TM TT UA UG US UZ VN KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT
LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 28430

English Abstract

The oral vaccines and oral vaccine adjuvants of the present invention are produced in transgenic plants and then administered through the consumption of the transgenic plant. DNA sequences both natural and synthetic encoding for the expression of immunogenic agents which are capable of causing an immune response in animals when fed in edible plants, plant tissues, or derived plant materials are constructed and plants transformed for stable or transient expression in plant cells. The present invention provides the first known functional method for immunizing animals via transgenic plants, where the plants express bacterial antigens that act as both immunogens and adjuvants when the transgenic plant material expressing the antigens is fed to animals.

French Abstract

Les vaccins oraux et leurs adjuvants de l'invention sont produits dans des plantes transgeniques puis administres par absorption d'une telle plante. On assemble des sequences d'ADN, naturelles ou synthetiques, qui codent pour l'expression d'agents immunogenes capables de provoquer une reponse immunitaire chez des animaux lorsqu'ils mangent ces plantes comestibles, des tissus vegetaux ou des elements derives de ces plantes, et on transforme des plantes pour qu'elles procedent a l'expression stable ou transitoire de telles sequences dans leurs cellules. L'invention concerne le premier procede fonctionnel connu permettant d'immuniser des animaux par l'intermediaire de plantes transgeniques qui expriment des antigenes bacteriens agissant tant comme immunogenes que comme adjuvants, quand les elements de plantes transgeniques exprimant ces antigenes sont absorbes par des animaux.

PCT FULLTEXT (Dialog® File 349): (c) . All rights reserved.

-
17. ☒ 2/3,AB/17 (Item 6 from file: 349)
00232603

SPERM SURFACE PROTEIN

PROTEINE DE SURFACE DE SPERMATOZOIDE

Patent Applicant/Assignee:

THE TRUSTEES OF PRINCETON UNIVERSITY,

SILVER Lee M,

TSAI Jen-Yue,

Inventor(s):

SILVER Lee M,

TSAI Jen-Yue,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9306859 A1 19930415

Application: WO 92US8457 19921005 (PCT/WO US9208457)

Priority Application: US 91592 19911004; US 92630 19920818

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AU BB BG BR CA CS FI HU JP KR LK MG MN MW NO PL RO RU SD US AT BE CH
DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD
TG

Publication Language: English

Fulltext Word Count: 18456

English Abstract

The present invention relates to a protein, termed t-complex associated testes expressed-1 (tcte-1) that is found on the surface of mature sperm and is responsible for the binding of sperm to egg during mammalian fertilization. The invention provides for tcte-1 nucleic acids, proteins, antibodies directed toward tcte-1, vaccines, and methods of immunocontraception.

French Abstract

La presente invention se rapporte a une proteine, appelee proteine 1 associee au complexe t et exprimee par les testicules (tcte-1), qui se trouve sur la surface de spermatozoides adultes, et qui est responsable de la fixation du spermatozoide sur l'ovule au cours de la fecondation chez les mammiferes. L'invention se rapporte egalement a des acides nucleiques de tcte-1, a des proteines de ce type, a des anticorps diriges contre tcte-1, a des vaccins et a des procedes d'immunocontraception.

PCT FULLTEXT (Dialog® File 349): (c) . All rights reserved.

-
18. ☒ 2/3,AB/18 (Item 1 from file: 636)
02783539 **Supplier Number:** 45647996

Vaccine Development Transgenic Plants May Advance Subunit Vaccines

Vaccine Weekly , p N/A

July 3 , 1995

Language: English **Record Type:** Fulltext

Document Type: Newsletter ; Trade

Word Count: 470

Gale Group Newsletter DB(TM) (Dialog® File 636): (c) 2006 The Gale Group. All rights reserved.

-
19. ☒ 2/3,AB/19 (Item 1 from file: 654)

0005788997

Derwent Accession: 2003-092957

Methods and compositions for stable transgenic plant

pharmaceuticals and their use as contraceptives

Inventor: Kirk, Dwayne, INV

Mason, Hugh, INV

Walmsley, Amanda, INV

Arntzen, Charles, INV

Assignee: Boyce Thompson Institute 02)

Correspondence Address: PALMER & DODGE, LLP KATHLEEN M. WILLIAMS, 111
HUNTINGTON AVENUE, BOSTON, MA, 02199, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040175440	A1	20040909	US 2003683611	20031010
Priority				WO 2002US11693	20020412

Fulltext Word Count: 39589

Abstract:

The present invention provides for processing methods that preserve pharmaceutical proteins expressed in plants. Herein raw plant tissue is reduced to a stable homogenate without significant loss of protein or pharmaceutical potency. The homogenate can be used directly for pharmaceutical purposes without the need to further extract, purify, or precipitate the pharmaceutical protein. The present invention further provides a method of effective immunocontraception for animal and human application. Methods are disclosed for producing transgenic plants or plant cells which express contraceptive proteins, and which can be delivered whole, in part, or after processing, to an animal to cause a contraceptive effect in the target species.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

20. ☒

2/3,AB/20 (Item 2 from file: 654)

5767580

Derwent Accession: 1999-610819

Utility

CERTIFICATE OF CORRECTION

**Sequence and method for genetic engineering of proteins with
cell membrane translocating activity**

Inventor: Lin, Yao-Zhong, Nashville, TN

Donahue, John P., Nashville, TN

Rojas, Mauricio, Nashville, TN

Tan, ZhongJia, Nashville, TN

Assignee: Vanderbilt University 02), Nashville, TN

Examiner: Low, Christopher S. F. (Art Unit: 163)

Assistant Examiner: Kam, Chih-Min

Law Firm: Needle & Rosenberg, P.C.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6780843	A	20040824	US 2002116288	20020404
Division	US 6432680	A		US 2000562868	20000501
Division	US 6248558	A		US 98186170	19981104

Fulltext Word Count: 2874

Abstract:

The invention describes a membrane-translocating peptide sequence (MTS) which facilitates entry of polypeptides and proteins into cells. Also described is an isolated nucleotide sequence encoding the

membrane-translocating peptide and a method of using this sequence to genetically engineer proteins with cell membrane permeability. The MTS, and the method of genetically engineering proteins with cell membrane permeability, are useful for polypeptide and protein delivery for human and veterinary applications such as vaccine delivery and cancer therapy.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

21. ☒ 2/3,AB/21 (Item 3 from file: 654)

0005619729

Derwent Accession: 2004-340011

Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating

Inventor: Short, Jay, INV

Correspondence Address: HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY, 10022, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	----	-----	-----
Main Patent	US 20040077090	A1	20040422	US 2003383798	20030306
Continuation	ABANDONED			US 2000677584	20000930
CIP	US 6605449			US 2000594459	20000614
CIP	US 6358709			US 2000522289	20000309
CIP	PENDING			US 2000498557	20000204
CIP	US 6479258			US 2000495052	20000131
Provisional				US 60-156815	19990929

Fulltext Word Count: 340496

Abstract:

An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

22. ☒ 2/3,AB/22 (Item 4 from file: 654)

0005619250

Derwent Accession: 2004-122882

Molecular antigen arrays

Inventor: Bachmann, Martin, INV
Tissot, Alain, INV

Pumpens, Paul, INV
Cielens, Indulis, INV
Renhofa, Regina, INV
Correspondence Address: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW
YORK AVENUE, N.W., WASHINGTON, DC, 20005, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040076611	A1	20040422	US 2003617876	20030714
Provisional				US 60-396126	20020717

Fulltext Word Count: 45783

Abstract:

The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

23. ☒ 2/3,AB/23 (Item 5 from file: 654)

0005368371

Derwent Accession: 2002-627351

Molecular antigen array

Inventor: Renner, Wolfgang, INV
Bachmann, Martin, INV
Tissot, Alain, INV
Maurer, Patrick, INV
Lechner, Franziska, INV
Sebbel, Peter, INV
Piossek, Christine, INV
Ortmann, Rainer, INV
Luond, Rainer, INV
Staufenbiel, Matthias, INV
Frey, Peter, INV

Assignee: Cytos Biotechnology AG 03)

Correspondence Address: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW
YORK AVENUE, N.W., WASHINGTON, DC, 20005, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030175711	A1	20030918	US 200250898	20020118
Provisional				US 60-331045	20011107
Provisional				US 60-326998	20011005
Provisional				US 60-288549	20010504
Provisional				US 60-262379	20010119

Fulltext Word Count: 92990

Abstract:

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or

antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

24. ☒ 2/3,AB/24 (Item 6 from file: 654)

0005367950

Derwent Accession: 2003-430264

Molecular antigen array

Inventor: Renner, Wolfgang, INV

Bachmann, Martin, INV

Tissot, Alain, INV

Maurer, Patrick, INV

Lechner, Franziska, INV

Sebbel, Peter, INV

Piossek, Christine, INV

Assignee: Cytos Biotechnology AG 03)

Correspondence Address: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030175290	A1	20030918	US 200250902	20020118
Provisional				US 60-331045	20011107
Provisional				US 60-326998	20011005
Provisional				US 60-288549	20010504
Provisional				US 60-262379	20010119

Fulltext Word Count: 105413

Abstract:

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

25. ☒ 2/3,AB/25 (Item 7 from file: 654)

0005208278

Derwent Accession: 1999-120787

Ligand for herpes simplex virus entry mediator and methods of use

Inventor: Carl Ware, INV

Correspondence Address: Robert M. Bedgood PILLSBURY WINTHROP LLP, 50
Fremont Street, San Francisco, CA, 94120, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030060605	A1	20030327	US 2001967604	20010928
CIP	PENDING			US 2000549096	20000412
CIP	US 6140467			US 97898234	19970730
Provisional				US 60-51964	19970707

Fulltext Word Count: 44859

Abstract:

A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpesvirus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders or those having or suspected of having a herpesvirus infection, utilizing p30 and the fusion proteins of the invention, are also provided.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

26. ☒ 2/3,AB/26 (Item 8 from file: 654)

0005088385

Derwent Accession: 1999-610819

**Sequence and method for genetic engineering of proteins with
cell membrane translocating activity**

Inventor: Yao-Zhong Lin, INV
John Donahue, INV
Mauricio Rojas, INV
ZhongJia Tan, INV

Assignee: Vanderbilt University 02)

Correspondence Address: NEEDLE & ROSENBERG P C, 127 PEACHTREE STREET N
E, ATLANTA, GA, 30303-1811, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20020143142	A1	20021003	US 2002116288	20020404
Division	PENDING			US 2000562868	20000501
Division	US 6248558			US 98186170	19981104
Provisional				US 60-80083	19980331

Fulltext Word Count: 15575

Abstract:

The invention describes a membrane-translocating peptide sequence (MTS) which facilitates entry of polypeptides and proteins into cells. Also described is an isolated nucleotide sequence encoding the membrane-translocating peptide and a method of using this sequence to genetically engineer proteins with cell membrane permeability. The MTS, and the method of genetically engineering proteins with cell membrane permeability, are useful for polypeptide and protein delivery for human and veterinary applications such as vaccine delivery and cancer therapy.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

27. ☒ 2/3,AB/27 (Item 9 from file: 654)

4728443

Derwent Accession: 1999-610819

Utility

**C/ Sequence and method for genetic engineering of proteins
with cell membrane translocating activity**

; ISOLATED FUSION PROTEINS WITH MEMBRANE-TRANSLOCATION PEPTIDE WITH AMINO
ACID SEQUENCE

Inventor: Lin, Yao-Zhong, Nashville, TN
Donahue, John P., Nashville, TN
Rojas, Mauricio, Nashville, TN
Tan, ZhongJia, Nashville, TN

Assignee: Vanderbilt University 02), Nashville, TN
Vanderbilt University (Code: 88418)

Examiner: Low, Christopher S. F. (Art Unit: 163)

Assistant Examiner: Kam, Chih-Min

Law Firm: Needle & Rosenberg, P.C.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6432680	A	20020813	US 2000562868	20000501
Division	US 6248558	A		US 98186170	19981104

Fulltext Word Count: 11349

Abstract:

The invention describes a membrane-translocating peptide sequence (MTS) which facilitates entry of polypeptides and proteins into cells. Also described is an isolated nucleotide sequence encoding the membrane-translocating peptide and a method of using this sequence to genetically engineer proteins with cell membrane permeability. The MTS, and the method of genetically engineering proteins with cell membrane permeability, are useful for polypeptide and protein delivery for human and veterinary applications such as vaccine delivery and cancer therapy.

US Pat.Full (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

28. ☒ 2/3,AB/28 (Item 10 from file: 654)

4687901

Derwent Accession: 1996-230602

Utility

CERTIFICATE OF CORRECTION

C/ Oral immunization with transgenic plants

; A DNA SEQUENCE ENCODING AN IMMUNOGENIC AGENT FROM ESCHERICHIA ENTEROTOXIN,
AND CHOLERA TOXIN; FOR PRODUCING TRANSGENIC PLANTS THAT ARE USED AS ANIMAL
FEED FOR ORAL IMMUNIZATION OF ANIMALS

Inventor: Arntzen, Charles J., Ithaca, NY
Mason, Hugh S., Ithaca, NY
Tariq, Haq A., San Antonio, TX
Clements, John D., New Orleans, LA

Assignee: The Texas A&M University System 02), College Station, TX
The Administrators of the Tulane Fund 02), New Orleans, LA
Texas A & M University System
Tulane Educational Fund Administrators of (Code: 00664 06116)

Examiner: Nelson, Amy J. (Art Unit: 168)

Assistant Examiner: Mehta, Ashwin
Law Firm: Fulbright & Jaworski, L.L.P.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6395964	A	20020528	US 97817906	19970804
PCT	WO 9612801		19960502	WO 95US13376	19951024
			371:19970804		
			102e:19970804		

Fulltext Word Count: 25221

Abstract:

The oral antigens and adjuvants of the present invention are produced in transgenic plants and then administered through the consumption of the transgenic plant. DNA sequences both natural and synthetic encoding for the expression of immunogenic agents which are capable of causing an immune response in animals when fed in edible plants, plant tissues, or derived plant materials are constructed, and plants transformed for stable or transient expression in plant cells. The present invention provides the first known functional method for immunizing animals via transgenic plants, where the plants express bacterial antigens that act as both immunogen and adjuvants when the transgenic plant material expressing the antigens is fed to animals.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

29. ☒

2/3,AB/29 (Item 11 from file: 654)

4525528

Derwent Accession: 1999-610819

Utility

**C/ Sequence and method for genetic engineering of proteins
with cell membrane translocating activity**

; POLYNUCLEOTIDE ENCODING AT LEAST EIGHT AMINO ACIDS FROM A DEFINED AMINO ACID SEQUENCE; VACCINE DELIVERY; DRUG DELIVERY OF ANTICARCINOGENIC AGENTS; TREATMENT OF GENETIC DISORDERS; STUDIES OF INTRACELLULAR PROCESSES IN LIVING SYSTEMS

Inventor: Lin, Yao-Zhong, Nashville, TN
Donahue, John P., Nashville, TN
Rojas, Mauricio, Nashville, TN
Tan, Zhong-Jia, Nashville, TN

Assignee: Vanderbilt University 02), Nashville, TN
Vanderbilt University (Code: 88418)

Examiner: Carlson, Karen Cochrane (Art Unit: 163)

Assistant Examiner: Srivastava, Devesh

Law Firm: Needle & Rosenberg, P.C.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6248558	A	20010619	US 98186170	19981104
Provisional				US 60-80083	19980331

Fulltext Word Count: 11817

Abstract:

The invention describes a membrane-translocating peptide sequence (MTS) which facilitates entry of polypeptides and proteins into cells. Also described is an isolated nucleotide sequence encoding the membrane-translocating peptide and a method of using this sequence to

genetically engineer proteins with cell membrane permeability. The MTS, and the method of genetically engineering proteins with cell membrane permeability, are useful for polypeptide and protein delivery for human and veterinary applications such as vaccine delivery and cancer therapy.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

30. ☒ 2/3,AB/30 (Item 12 from file: 654)

4465590

Derwent Accession: 1996-230602

Utility

C/ **Oral immunization with transgenic plants**

; SYNTHETIC ESCHERICHIA COLI GENE WHICH ENCODES LT-B; THE DNA SEQUENCE IS OPTIMIZED FOR PLANT CODON USAGE; FEEDS; FOODS

Inventor: Arntzen, Charles J., Ithaca, NY

Mason, Hugh S., Ithaca, NY

Haq, Tariq A., San Antonio, TX

Assignee: Texas A & M University System 02), College Station, TX

Texas A & M University System (Code: 06116)

Examiner: Bui, Phuong T. (Art Unit: 168)

Law Firm: Fulbright & Jaworski, L.L.P.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6194560	A	20010227	US 98191852	19981112
Division	Abandoned			US 817906	
CIP	Abandoned			US 94328716	19941024

Fulltext Word Count: 24738

Abstract:

The oral vaccines and oral vaccine adjuvants of the present invention are produced in transgenic plants and then administered through the consumption of the transgenic plant. DNA sequences both natural and synthetic encoding for the expression of immunogenic agents which are capable of causing an immune response in animals when fed in edible plants, plant tissues, or derived plant materials are constructed and plants transformed for stable or transient expression in plant cells. The present invention provides the first known functional method for immunizing animals via transgenic plants, where the plants express bacterial antigens that act as both immunogens and adjuvants when the transgenic plant material expressing the antigens is fed to animals.

US Pat.Full. (Dialog® File 654): (c) Format only 2006 Dialog. All rights reserved.

<input checked="" type="checkbox"/> Select All	Print/Save Selected	Send Results	Display Selected	Format
<input checked="" type="checkbox"/> Clear Selections				Free

© 2006 Dialog, a Thomson business

Hit List

[First Hit](#)

[Clear](#)

[Generate Collection](#)

[Print](#)

[Fwd Refs](#)

[Bkwd Refs](#)

[Generate OACS](#)

Search Results - Record(s) 1 through 10 of 11 returned.

☐ 1. Document ID: US 20060160759 A1

L4: Entry 1 of 11

File: PGPB

Jul 20, 2006

PGPUB-DOCUMENT-NUMBER: 20060160759

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060160759 A1

TITLE: Influenza therapeutic

PUBLICATION-DATE: July 20, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Chen; Jianzhu	Brookline	MA	US
Ge; Qing	Cambridge	MA	US
Eisen; Herman N.	Waban	MA	US

US-CL-CURRENT: [514/44](#); [435/5](#), [536/23.1](#)

Full	Title	Citation	Front	Review	Classification	Data	Reference	Sequences	Attachments	Claims	BMC	Drawings
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	--------------------------

☐ 2. Document ID: US 20060101539 A1

L4: Entry 2 of 11

File: PGPB

May 11, 2006

PGPUB-DOCUMENT-NUMBER: 20060101539

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060101539 A1

TITLE: Cryopreservation of cells

PUBLICATION-DATE: May 11, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ainley; William Michael	Carmel	IN	US
Leatherman Larsen; Cory Michelle	Zionsville	IN	US
Lu; Min	Carmel	IN	US
Shen; Liu Yin	Westfield	IN	US
Jayakumar; Pon Samuel	Carmel	IN	US
Garrison; Robbi Janette	Fillmore	IN	US

Pareddy; Dayakar Reddy
Beringer; Jeffrey Richard

Carmel IN US
Carmel IN US

US-CL-CURRENT: 800/278; 435/419

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGs	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20060003444 A1

L4: Entry 3 of 11

File: PGPB

Jan 5, 2006

PGPUB-DOCUMENT-NUMBER: 20060003444
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060003444 A1

TITLE: Cells for detection of influenza and parainfluenza viruses

PUBLICATION-DATE: January 5, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Huang; Yung T.	Richmond Heights	OH	US

US-CL-CURRENT: 435/325; 435/235.1, 435/6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGs	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20050048074 A1

L4: Entry 4 of 11

File: PGPB

Mar 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050048074
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050048074 A1

TITLE: Vectors and cells for preparing immunoprotective compositions derived from transgenic plants

PUBLICATION-DATE: March 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Cardineau, Guy A.	Tempe	AZ	US
Mason, Hugh Stanley	Phoenix	AZ	US
VanEck, Joyce M.	Ithaca	NY	US
Kirk, Dwayne D.	Mesa	AZ	US
Walmsley, Amanda Maree	Mesa	AZ	US

US-CL-CURRENT: 424/186.1; 424/9.2, 435/320.1, 435/419, 536/23.72, 800/278

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20040268442 A1

L4: Entry 5 of 11

File: PGPB

Dec 30, 2004

PGPUB-DOCUMENT-NUMBER: 20040268442

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040268442 A1

TITLE: Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production

PUBLICATION-DATE: December 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Miller, Timothy Joe	Lincoln	NE	US
Fanton, Matthew James	Lincoln	NE	US
Webb, Steven Robert	Westfield	IN	US

US-CL-CURRENT: 800/288; 435/468

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20040234947 A1

L4: Entry 6 of 11

File: PGPB

Nov 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040234947

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040234947 A1

TITLE: Cells for detection of influenza and parainfluenza viruses

PUBLICATION-DATE: November 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Huang, Yung T.	Richmond Heights	OH	US

US-CL-CURRENT: 435/5; 435/366

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20040175440 A1

L4: Entry 7 of 11

File: PGPB

Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175440
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040175440 A1

TITLE: Methods and compositions for stable transgenic plant pharmaceuticals and their use as contraceptives

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kirk, Dwayne	Mesa	AZ	US
Mason, Hugh	Phoenix	AZ	US
Walmsley, Amanda	Mesa	AZ	US
Arntzen, Charles	Superstition Mountain	AZ	US

US-CL-CURRENT: 424/725; 424/130.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 6991899 B2

L4: Entry 8 of 11

File: USPT

Jan 31, 2006

US-PAT-NO: 6991899

DOCUMENT-IDENTIFIER: US 6991899 B2

**** See image for Certificate of Correction ****

TITLE: Cells for detection of influenza and parainfluenza viruses

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20040234947 A1	November 25, 2004

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 6610474 B1

L4: Entry 9 of 11

File: USPT

Aug 26, 2003

US-PAT-NO: 6610474

DOCUMENT-IDENTIFIER: US 6610474 B1

TITLE: Cells for detection of influenza and parainfluenza viruses

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 10. Document ID: BR 200410342 A, WO 2004098530 A2, US 20040268442 A1, EP

DERWENT-ACC-NO: 2004-813973

DERWENT-WEEK: 200643

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Making immunoprotective particles or biologically active protein particles, for stimulating immune response, by culturing plant cells transformed with the protein, and physically disrupting the cells to extract the proteins

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	DOC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
transgenic same (avian or poultry or bird or chicken) adj influenza	11

Display Format: ☐

Change Format

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

[First Hit](#) [Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 11 through 11 of 11 returned.

☐ 11. Document ID: CN 1333370 A

L4: Entry 11 of 11

File: DWPI

Jan 30, 2002

DERWENT-ACC-NO: 2002-292920

DERWENT-WEEK: 200234

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Crops capable of resisting virus diseases of poultry and production method thereof

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Publ	Draw
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Terms	Documents
transgenic same (avian or poultry or bird or chicken) adj influenza	11

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[First Hit](#) [Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 11 through 15 of 15 returned.

☐ 11. Document ID: WO 2004098533 A2

L3: Entry 11 of 15

File: EPAB

Nov 18, 2004

PUB-NO: WO2004098533A2

DOCUMENT-IDENTIFIER: WO 2004098533 A2

TITLE: VECTORS AND CELLS FOR PREPARING IMMUNOPROTECTIVE COMPOSITIONS DERIVED FROM TRANSGENIC PLANTS

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	EMC	Grant Doc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	-----	-----------

☐ 12. Document ID: CN 1333370 A

L3: Entry 12 of 15

File: DWPI

Jan 30, 2002

DERWENT-ACC-NO: 2002-292920

DERWENT-WEEK: 200234

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Crops capable of resisting virus diseases of poultry and production method thereof

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	EMC	Grant Doc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	-----	-----------

☐ 13. Document ID: GB 2282139 A

L3: Entry 13 of 15

File: DWPI

Mar 29, 1995

DERWENT-ACC-NO: 1995-117533

DERWENT-WEEK: 199516

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Transforming bird cells with exogenous nucleic acid - adsorbed on particles introduced by bombardment, is rapid and specific for germ line cells

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	EMC	Grant Doc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	-----	-----------

☐ 14. Document ID: GB 2229440 A, AU 648502 B, AU 9052879 A, EP 463047 A, JP 04504056 W, WO 9011355 A

L3: Entry 14 of 15

File: DWPI

Sep 26, 1990

DERWENT-ACC-NO: 1990-292652
DERWENT-WEEK: 199039
COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Introducing foreign nucleic acid into birds - by introducing explanted primordial germ cells contg. the nucleic acid into an embryo

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 15. Document ID: WO 8901972 A, AU 8823844 A, US 5175385 A

L3: Entry 15 of 15

File: DWPI

Mar 9, 1989

DERWENT-ACC-NO: 1989-085546
DERWENT-WEEK: 198911
COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Virus- resistant trans-genic animals - contg. cells bearing a gene coding on expression for an interferon of a different animal species

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
transgenic same Newcastle	15

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[First Hit](#) [Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 1 through 10 of 15 returned.

☐ 1. Document ID: US 20060101539 A1

L3: Entry 1 of 15

File: PGPB

May 11, 2006

PGPUB-DOCUMENT-NUMBER: 20060101539

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060101539 A1

TITLE: Cryopreservation of cells

PUBLICATION-DATE: May 11, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ainley; William Michael	Carmel	IN	US
Leatherman Larsen; Cory Michelle	Zionsville	IN	US
Lu; Min	Carmel	IN	US
Shen; Liu Yin	Westfield	IN	US
Jayakumar; Pon Samuel	Carmel	IN	US
Garrison; Robbi Janette	Fillmore	IN	US
Pareddy; Dayakar Reddy	Carmel	IN	US
Beringer; Jeffrey Richard	Carmel	IN	US

US-CL-CURRENT: [800/278](#); [435/419](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	I/M/C	Drawings
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	-----------------------	--------------------------

☐ 2. Document ID: US 20050239069 A1

L3: Entry 2 of 15

File: PGPB

Oct 27, 2005

PGPUB-DOCUMENT-NUMBER: 20050239069

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050239069 A1

TITLE: Screening method to identifying protective substances for the treatment of nerve degenerative and/or ischemic disorders

PUBLICATION-DATE: October 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
------	------	-------	---------

Maurer, Martin	Heidelberg	DE
Kuschinsky, Wolfgang	Heidelberg	DE
Schneider, Armin	Heidelberg	DE
Bach, Alfred	Edingen-Neckarhausen	DE

US-CL-CURRENT: 435/6; 435/7.21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20050048074 A1

L3: Entry 3 of 15

File: PGPB

Mar 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050048074
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20050048074 A1

TITLE: Vectors and cells for preparing immunoprotective compositions derived from transgenic plants

PUBLICATION-DATE: March 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Cardineau, Guy A.	Tempe	AZ	US
Mason, Hugh Stanley	Phoenix	AZ	US
VanEck, Joyce M.	Ithaca	NY	US
Kirk, Dwayne D.	Mesa	AZ	US
Walmsley, Amanda Maree	Mesa	AZ	US

US-CL-CURRENT: 424/186.1; 424/9.2, 435/320.1, 435/419, 536/23.72, 800/278

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20040268442 A1

L3: Entry 4 of 15

File: PGPB

Dec 30, 2004

PGPUB-DOCUMENT-NUMBER: 20040268442
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20040268442 A1

TITLE: Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production

PUBLICATION-DATE: December 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Miller, Timothy Joe	Lincoln	NE	US

Fanton, Matthew James	Lincoln	NE	US
Webb, Steven Robert	Westfield	IN	US

US-CL-CURRENT: 800/288; 435/468

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 5. Document ID: US 20040175440 A1

L3: Entry 5 of 15

File: PGPB

Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175440
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20040175440 A1

TITLE: Methods and compositions for stable transgenic plant pharmaceuticals and their use as contraceptives

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kirk, Dwayne	Mesa	AZ	US
Mason, Hugh	Phoenix	AZ	US
Walmsley, Amanda	Mesa	AZ	US
Arntzen, Charles	Superstition Mountain	AZ	US

US-CL-CURRENT: 424/725; 424/130.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 6. Document ID: US 20030191076 A1

L3: Entry 6 of 15

File: PGPB

Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030191076
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030191076 A1

TITLE: Prime-boost vaccination strategy

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Wesselingh, Steve	Vic		AU
Dry, Ian Barry	S.A.		AU
Strugnell, Richard Anthony	Vic		AU
Ramshaw, Ian Allister	Act		AU

US-CL-CURRENT: 514/44; 424/750, 424/751, 424/774, 424/777, 800/288

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 7. Document ID: US 20030049606 A1

L3: Entry 7 of 15

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049606

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049606 A1

TITLE: Novel anti-viral and anti-proliferative agents derived from STAT1 transcription factor

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Koromilas, Antonis E.	Montreal	NY	CA
Hoi-Tao Wong, Andrew	Brooklyn		US

US-CL-CURRENT: 435/5; 424/143.1, 424/159.1, 530/300, 530/388.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 8. Document ID: US 20020127204 A1

L3: Entry 8 of 15

File: PGPB

Sep 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020127204

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020127204 A1

TITLE: IMPROVEMENTS IN OR RELATING TO PROTECTION AGAINST INTRACELLULAR INFECTION

PUBLICATION-DATE: September 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
RUSSELL, STEPHEN JAMES	CAMBRIDGE		GB

US-CL-CURRENT: 424/93.1; 435/320.1, 435/325, 435/455, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 9. Document ID: US 6830923 B1

L3: Entry 9 of 15

File: USPT

Dec 14, 2004

US-PAT-NO: 6830923
DOCUMENT-IDENTIFIER: US 6830923 B1

TITLE: Genetics units for inhibiting the function of RNA

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	PubC	Draw. Co
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 10. Document ID: US 6689600 B1

L3: Entry 10 of 15

File: USPT

Feb 10, 2004

US-PAT-NO: 6689600
DOCUMENT-IDENTIFIER: US 6689600 B1
** See image for Certificate of Correction **

TITLE: Formulation of adenovirus for gene therapy

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	PubC	Draw. Co
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
transgenic same Newcastle	15

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

31aug06 07:08:47 User233831 Session D327.1
 \$0.42 0.121 DialUnits File1
 \$0.42 Estimated cost File1
 \$0.42 Estimated cost this search
 \$0.42 Estimated total session cost 0.121 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2006/Aug W4
 (c) 2006 The Thomson Corporation
 File 55:Biosis Previews(R) 1993-2006/Aug W4
 (c) 2006 The Thomson Corporation
 File 54:FOODLINE(R): Market 1979-2006/Aug 29
 (c) 2006 LFRA
 File 155:MEDLINE(R) 1950-2006/Aug 30
 (c) format only 2006 Dialog
 File 144:Pascal 1973-2006/Aug W1
 (c) 2006 INIST/CNRS
 File 73:EMBASE 1974-2006/Aug 31
 (c) 2006 Elsevier B.V.
 File 344:Chinese Patents Abs Jan 1985-2006/Jan
 (c) 2006 European Patent Office
 File 35:Dissertation Abs Online 1861-2006/Jun
 (c) 2006 ProQuest Info&Learning

Set Items Description
 --- -----

?

Ref	Items	Index-term
E1	1	MILLER TEST
E2	1	MILLER THEOREM
E3	0	*MILLER TIMOTHY J.
E4	1	MILLER TUCKER ZEMLIN CONSTRAINT
E5	2	MILLER UNITS
E6	1	MILLER UREY EVOLUTIONARY SIGNIFICANCE
E7	2	MILLER UREY EXPERIMENT
E8	1	MILLER V
E9	9	MILLER V. HCA, INC.
E10	1	MILLER V. KENNEDY
E11	1	MILLER V. RHODE ISLAND HOSPITAL
E12	2	MILLER V. SPICER

Enter P or PAGE for more

?

? e au-Miller T.J.

Ref	Items	Index-term
E1	1	AU-IDEA 6 MHZ TRANSDUCER
E2	154	AU-LAIT SPOTS //CAFE
E3	0	*AU-MILLER T.J.
E4	1	AU-MINERALISATION
E5	2	AU-MOTIF-DIRECTED DISPLAY
E6	5	AU-NI
E7	2	AU-PAGE WESTERN BLOT
E8	1	AU-PB ET AU-BI
E9	1	AU-PB-BI-S
E10	1	AU-PD
E11	2	AU-PNUT ADVISORY
E12	2	AU-PNUTS

Enter P or PAGE for more
? e au=Miller J. Timothy

Ref	Items	Index-term
E1	171	AU=MILLER J Z
E2	1333	AU=MILLER J.
E3	0	*AU=MILLER J. TIMOTHY
E4	2	AU=MILLER J.-J.
E5	5	AU=MILLER J.-J.R.
E6	4	AU=MILLER J.-M.
E7	6	AU=MILLER J.-N.H.
E8	407	AU=MILLER J.A.
E9	2	AU=MILLER J.A. JR.
E10	20	AU=MILLER J.A.A.
E11	2	AU=MILLER J.A.C.
E12	2	AU=MILLER J.A.D.

Enter P or PAGE for more
? e au=Fanton M. J.

Ref	Items	Index-term
E1	18	AU=FANTON M C
E2	1	AU=FANTON M.
E3	0	*AU=FANTON M. J.
E4	7	AU=FANTON M.C.
E5	1	AU=FANTON O
E6	1	AU=FANTON OLIVIER
E7	1	AU=FANTON P
E8	1	AU=FANTON P L
E9	2	AU=FANTON P.L.
E10	1	AU=FANTON PIERRE
E11	2	AU=FANTON R
E12	1	AU=FANTON R.

Enter P or PAGE for more
? e au=Fanton Matthew J.

Ref	Items	Index-term
E1	1	AU=FANTON M.
E2	7	AU=FANTON M.C.
E3	0	*AU=FANTON MATTHEW J.
E4	1	AU=FANTON O
E5	1	AU=FANTON OLIVIER
E6	1	AU=FANTON P
E7	1	AU=FANTON P L
E8	2	AU=FANTON P.L.
E9	1	AU=FANTON PIERRE
E10	2	AU=FANTON R
E11	1	AU=FANTON R.
E12	2	AU=FANTON ROBERT

Enter P or PAGE for more
? logoff

```
3laug06 07:10:32 User233831 Session D327.2
$0.35      0.058 DialUnits File5
$0.35 Estimated cost File5
$0.61      0.101 DialUnits File55
$0.61 Estimated cost File55
$0.45      0.087 DialUnits File54
```

\$0.45 Estimated cost File54
\$0.25 0.072 DialUnits File155
\$0.25 Estimated cost File155
\$0.46 0.101 DialUnits File144
\$0.46 Estimated cost File144
\$1.13 0.101 DialUnits File73
\$1.13 Estimated cost File73
\$0.60 0.058 DialUnits File344
\$0.60 Estimated cost File344
\$0.47 0.116 DialUnits File35
\$0.47 Estimated cost File35
OneSearch, 8 files, 0.694 DialUnits FileOS
\$0.53 TELNET
\$4.85 Estimated cost this search
\$5.27 Estimated total session cost 0.815 DialUnits

Logoff: level 05.12.03 D 07:10:32

You are now logged off



'T S2/3,AB/1-30' - No matching display code(s) found in file(s): 135

- For more records, click the Records link at page end.
- To change the format of selected records, select format and click **Display Selected**.
- To print/save clean copies of selected records from browser click **Print/Save Selected**.
- To have records sent as hardcopy or via email, click **Send Results**.

<input checked="" type="checkbox"/> Select All	Print/Save Selected	Send Results	Display Selected	Format Free
<input checked="" type="checkbox"/> Clear Selections				

Dialog eLink:

USPTO Full Text Retrieval Options

[open url](#)

[open url](#)

1. ☒ 2/3,AB/1 (Item 1 from file: 5)

0009845382 Biosis No.: 199598313215

Oral immunization with a recombinant bacterial antigen produced in transgenic plants

Author: Haq Tariq A; Mason Hugh S; Clements John D; Arntzen Charles J (Reprint)

Author Address: Plant Biotechnol. Program, Albert B. Alkek Inst. Biosci. Technol., Texas A and M Univ., 2121 Holcombe Blvd., Houston, TX 77030, USA**USA

Journal: Science (Washington D C) 268 (5211): p 714-716 1995 1995

ISSN: 0036-8075

Document Type: Article

Record Type: Abstract

Language: English

Abstract: The binding subunit of Escherichia coli heat-labile enterotoxin (LT-B) is a highly active oral immunogen. Transgenic tobacco and potato plants were made with the use of genes encoding LT-B or an LT-B fusion protein with a microsomal retention sequence. The plants expressed the foreign peptides, both of which formed oligomers that bound the natural ligand. Mice immunized by gavage produced serum and gut mucosal anti-LT-B immunoglobulins that neutralized the enterotoxin in cell protection assays. Feeding mice fresh transgenic potato tubers also caused oral immunization.

Biosis Previews(R) (Dialog® File 5): (c) 2006 The Thomson Corporation. All rights reserved.

Dialog eLink:

USPTO Full Text Retrieval Options



[open url](#)

[open url](#)

2. ☒ 2/3,AB/2 (Item 1 from file: 24)

0002637506 IP Accession No: 6025592

A role for lymphotoxin in the acquisition of Ly49 receptors during NK cell development

Lian, Rebecca H; Chin, Robert K; Nemeth, Hajnalka E; Libby, Shon L; Fu, Yang-Xin; Kumar, Vinay The Department of Pathology, University of Chicago, Chicago, USA,
[mailto:rlan@bsd.uchicago.edu]

European Journal of Immunology , v 34 , n 10 , p 2699-2707 , 2004

Publication Date: 2004

Publisher: Wiley-VCH, Postfach 101161 Weinheim 69451 Germany, [mailto:info@wiley-vch.de], [URL:http://www.wiley-vch.de/publish/en/]